ESMO 2022 Conference Coverage
ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Injection of Abiraterone Decanoate in Patients With Prostate Cancer
By
ESMO 2022 Conference Coverage
FEATURING
Jose Avitia
By
ESMO 2022 Conference Coverage
FEATURING
Jose Avitia
Login to view comments.
Click here to Login
